Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will present new data on minimal residual disease (MRD) negativity rates from the Phase 3 CARTITUDE-4 trial ...

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments. One of these, lecanemab ...

Patients with Huntington’s disease have a genetic mutation that triggers proteins to misfold and clump together in the brain.

Scientists at Northwestern and Case Western Reserve universities have developed the first polymer-based therapeutic for Huntington's disease, an ...

Brad Axis Brain and Back Institute +1 (817) 502-7411 ... Visit us on social media: Facebook X LinkedIn YouTube ...

When you think of the YMCA, you might think of working out. But the "Y's" Thriver's Club is about more than making your ...

Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic ...

Living with a chronic pain condition can make everyday tasks more challenging. For some people in Southern Utah dealing with ...

Cantargia (Cantargia AB); (Nasdaq Stockholm:CANTA) today announced new clinical results from two nadunolimab combination therapy trials ...

Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be ...

Research shows neuropathy can be more severe and more common in Black breast cancer patients, causing doctors to dial back ...